GlassScriptPhysician profile
Nam Nguyen
NPI 1477895787
$1,737.61
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.83 · 2021: $28.09 · 2022: $168 · 2023: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $825 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $825.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teladoc Health, INC. | $1,525.00 | 2023 | |
| Incyte Corporation | $107.18 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $72.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $16.83 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.62 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nam Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.